Leflunomide, a DHODH inhibitor, was identified as an inhibitor of neural crest cell development by chemical screening, and A771726 also decreased melanoma cell growth in combination with GREB1 Is4 targeting (Fig. 7H). This evidence concerns the gene GREB1 and melanoma.